Company intelligence / Profile preview
AlgoSource
Saint-Nazaire, Pays de la Loire, Francealgosource.com ↗
- Ownership
- Private
- Employees
- ~37
- Development stage
- Commercial
01
Overview
AlgoSource has demonstrated the effectiveness of its spirulina liquid extract in a clinical trial targeting NASH syndrome. The company is also developing AmiTher, a microalgae-based solution to reduce side effects of cancer therapies, with planned hospital-based clinical trials. Products are subject to internal/external quality controls before market release.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Microalgae-derived functional ingredientsNatural extracts
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
University of Nantes & Center for Human Nutrition Research “Ouest” (clinical research collaboration)Alpha Biotech (industrial production partnership/historical link)Pôle Mer Bretagne Atlantique cluster ("AmiTher" labeled by this cluster)
Beyond the preview
Go deeper on AlgoSource.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlgoSource.